Abstract Potent and selective adenosine A 1 receptor (A 1 AR) antagonists with favourable pharmacokinetic properties used as novel diuretics and antihypertensives are desirable. Thus, we designed and synthesized a series of novel 4-alkylamino substitution-2-arylpyrazolo[4,3-c]quinolin-3-one derivatives. The aim of the present study is to characterize the biological profiles of the optimized compound, PQ-69. In vitro binding assay revealed a K i value of 0.96 nM for PQ-69 in cloned hA 1 receptor, which was 217-fold more selective compared with hA 2A receptors and >1,000-fold selectivity for hA 1 over hA 3 receptor. The results obtained from [ 35 S]-GTPγS binding and cAMP concentration assays indicated that PQ-69 might be an A 1 AR antagonist with inverse agonist activity. In addition, PQ-69 displayed highly inhibitory activities on isolated guinea pig contraction (pA2 value of 8.99) induced by an A 1 AR agonist, 2-chloro-N6-cyclopentyl adenosine. Systemic administration of PQ-69 (0.03, 0.3, 3 mg/kg) increased urine flow and sodium excretion in normal rats. Furthermore, PQ-69 displayed better metabolic stability in vitro and longer terminal elimination half-life (t 1/2 ) in vivo compared with 1,3-dipropyl-8-cyclopentylxanthine. These findings suggest that PQ-69 exhibits potent antagonist effects on A 1 AR in vitro, ex vivo and in vivo, it might be a useful research tool for investigating A 1 AR function, and it could be developed as a potential therapeutic agent.
Introduction
Adenosine is an important endogenous modulator with a large variety of physiological functions acting on four different adenosine receptor (AR) subtypes, named A 1 , A 2A , A 2B and A 3 . Upon activation, A 1 and A 3 AR may inhibit adenylyl cyclase, which results in a decrease in cyclic AMP level and stimulates phospholipase C and phospholipase D via G i/o protein, whereas the A 2A and A 2B ARs are stimulatory to adenylyl cyclase via G s protein. Adenosine A1 receptor (A 1 AR) activation can also activate several types of K + channels and mitogen-activated protein kinases (MAPK) via β,γ-subunits released from G i/o proteins, and also inhibits N-type Ca 2+ currents via PTX-sensitive pathways [1] . A 1 ARs are expressed in large numbers in the brain, as well as in peripheral tissues including kidney, heart and liver [2] . Because of adenosine exerting different physiological effects, a large number of A 1 AR antagonists exhibit a plethora of actions including anti-hypertensive, anti-depressive, anti-diabetic, anti-Parkinson and anti-hyperanalgesic effects [3] . In the kidney, the importance of A 1 ARs has been confirmed in regulation of fluid balance [4] . Induction of diuresis and natriuresis without reducing renal function is therapeutically desirable in treatment of patients with renal dysfunction. Therefore, a large number of potent and selective A 1 AR antagonists with structural diversity have been developed, including xanthinic or non-xanthinic scaffolds [5] . However, relatively few molecular entities have been realized in clinical application, mainly because of unsatisfactory pharmacokinetic properties and the complications of species differences between humans and animals, as well as differences in expression pattern of second Min Lu and Bo Wang contributed equally to this work.
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The online version of this article (doi:10.1007/s11302-014-9424-5) contains supplementary material, which is available to authorized users. messenger systems [6] . Pharmacological differences in terms of neutral antagonists and inverse agonists, however, have been determined [7] . In the AR research field, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, an agent with a xanthinic scaffold) is widely used as a reference A 1 R antagonist in preclinical studies. Interestingly, DPCPX has been identified as an inverse agonist in different systems with constitutive A 1 R activity [8, 9] . Rolofylline (KW3902, a more selective and potent A 1 R antagonist) also acts as an adenosine A 1 R inverse agonist to inhibit osteoclast differentiation.
Inverse agonists and neutral antagonists were thought to act via different signal transduction mechanisms. Despite these obstacles, potent and selective non-xanthinic selective A 1 AR antagonists with favourable pharmacokinetic properties draw the investigators' attention because of their many potential therapeutic applications. Most of the non-xanthinic adenosine receptor antagonists are nitrogen-containing heterocyclic compounds. In our laboratory, a series of novel tricyclic heteroaromatic derivatives were designed and synthesized. Based on the 3D-QSAR model derived from the quantitative structure-activity relationship analysis of a set of imidazo[1,2-a]quinoxaline molecules [10] with structural diversity, some important structural insights into the interaction between non-xanthinic ligands with A 1 AR have been obtained, including hydrophobic interactions, hydrogen bond acceptors and hydrogen bond donors. Aided by this important structural information, a series of novel 4-alkylamino substitution 2-arylpyrazolo[4,3-c]quinolin-3-one derivatives were designed and synthesized in our laboratory. The biological activity study of these tricyclic heteroaromatic derivatives was focused on the evaluation of selectivity of A 1 AR as an antagonist. A potent and selective A 1 AR antagonist, 4-butylamino-2-(3-fluorophenyl) [4, 3-c] quinolin-3-one (PQ-69), was identified through receptor radioligand binding assay. In the present study, we studied PQ-69 affinity to A 1 , A 2A and A 3 AR and selectivity between A 1 AR and A 2A AR in radioligand binding assay, and post-receptor G protein coupling properties of PQ-69 in cell lines stably expressing the human A 1 AR. Further, we observed the inverse agonist activity of PQ-69 compared with DPCPX in cell lines. We also evaluated PQ-69 antagonist activity on isolated guinea pig tracheal strips. Furthermore, we found that PQ-69 displayed diuresis and natriuresis bioactivities in in vivo studies using normal rats.
Materials and methods

Chemistry
Solvents and reagents were commercially purchased from Sigma-Aldrich Chemical Company unless otherwise noted. All reactions were monitored by thin layer chromatography (TLC) on 25×75 mm glass slides precoated with silica gel (GF 254 ) to a thickness of 0.25 mm and viewed at 254-nm UV light. Column chromatography for product purification was performed using silica gel of 200-300 mesh. Melting points (mp) were determined using a RY-1 apparatus and are uncorrected. Hydrogen-1 NMR ( 1 H NMR) spectra were recorded on Varian Unity Inova 600 MHz and JNM-ECA-400 400 MHz instrument. The chemical shifts are reported in δ (ppm) and are relative to the central peak of the solvent that is always DMSO-d6. Mass spectra were obtained from Micromass ZabSpec and API3000 instruments. Elemental analysis for N, H and N was performed with CarloErba-1106 and the results were within ±0.5 % of the theoretical unless otherwise stated. All reported compounds show 1 H NMR and mass spectra in agreement with the assigned structures.
General method for the synthesis of PQ-69 and its analogues 2,4-Dihydroxy-3-quinolinecarboxylic acid ethyl ester and its analogues (II) To gain a solution of diethyl malonate (0.78 mol) in dry matter of fermented filtrate (DMF) (120 mL), sodium hydride (0.31 mol) was added partwise at room temperature. The suspension was stirred 30 min at 70°C and the solution of isatoic anhydride (0.26 mol) in DMF (250 mL) was added dropwise during 1 h. The mixture was stirred for 5 h at 120°C. After the resulting mixture was cooled to 0°C, the precipitant was collected through filtering and dissolved with 200-mL H 2 O. The DMF filtrate was concentrated under reduced pressure and the resulting residue was also dissolved with 150-mL H 2 O. The combined aqueous phase was adjusted by HCl until the pH value was between 3-4, the resulting precipitant was collected and washed with water and dried under ambient condition. The crude was recrystallized by using ethyl acetate to afford II (44 g, 73 % yield) as pale yellow crystal, m.p. 206-208°C.
2,4-Dichloro-3-quinolinecarboxylic acid ethyl ester and its analogues (III) A mixture of compounds (II) (0.12 mol), phosphorus oxychloride (160 mL) and phosphorus pentachloride (5 g) was stirred at 100-115°C for 3 h. Evaporation of the excess phosphorus oxychloride at reduced pressure gave a residue that was treated with ice water (500 mL). The aqueous solution was extracted twice with dichloromethane (250 mL). The combined organic phase was dried over MgSO 4 , filtered and concentrated under reduced pressure. The solid was recrystallized by using ethyl acetate to afford III (26.2 g, 80.5 % yield) as pale yellow crystal, m.p. 100-101°C.
2-Alkylamino substituted 4-chloride-3-quinolinecarboxylic acid ethyl ester and its analogues (IV) A mixture of 2,4-dichloro compounds (III) (40 mmol) and n-butylamine (160 mmol) in methanol (120 mL) was refluxed for 8 h. The reaction mixture was concentrated under reduced pressure and the resulting residue was purified using silica gel column chromatography (CH 2 Cl 2 /MeOH=10:1) to afford IV (7.8 g, 63.2 % yield) as a pale yellow waxy solid.
PQ-69 and its analogues (V) To gain a solution of compounds (IV) (1.5 mmol) in ethanol (30 mL), a mixture of 3-fluorophenylhydrazine (4.5 mmol) and triethylamine (4.5 mmol) in ethanol (20 mL) was added dropwise. The reaction mixture was refluxed under N 2 for 24 h and concentrated under reduced pressure and the resulting residue was subjected to purification using silica gel column chromatography (CH 2 Cl 2 /MeOH=50:1) to afford PQ-69 (0.16 g, 30.8 % yield) as a white crystal, m.p. 204-206°C.
Chemicals
Dulbecco's modified Eagle medium with nutrient mixture F12 (DMEM/F12) medium, foetal calf serum and geneticin (G418) were obtained from Gibco (Grand Island, NY, USA). -(1-methyl-2-phenylethyl) adenosine (R-PIA), 5′-(N-ethylcarboxamido) adenosine (NECA), 2-chloro-N 6 -cyclopentyl adenosine (CCPA), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), forskolin, histamine, furosemide (FURO), hydrochlorothiazide (HCTZ), polyethyleneglycol 400 (PEG400), internal standard solution, NADPH and all other reagents were purchased from SigmaAldrich (St. Louis, MO, USA). Acetonitrile and other reagents used in pharmacokinetic evaluation were all of analytical grade (J&K Chemical Ltd., Beijing, China). Pooled human liver microsomes (protein content of 20 g/L, batch no. 18888) were purchased from BD Gentest (Woburn, MA, USA). Rat liver microsomes were prepared by differential centrifugation [11] , and the protein concentration of the microsomes was determined using the Lowry method.
Cell culture
Chinese hamster ovary cells (CHO) and human embryonic kidney 293 cells (HEK-293) were, respectively, transfected with the recombinant hA 1 AR, hA 2A AR and hA 3 AR using the calcium phosphate precipitation. The CHO-hA 1 , HEK-293-hA 2A and CHO-hA 3 cells with the highest expression level were cultured in DMEM/F12 medium containing 10 % foetal calf serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine and 400 μg/mL geneticin at 37°C in 5 % CO 2 /95 % air.
Membrane preparation
Cell membranes were prepared as previously described with slight modification [12] . After washing twice with ice-cold phosphate-buffered saline, the cultured cells were detached by incubation with Versene buffer (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 ·12 H 2 O, 1 mM glucose·H 2 O, 2 mM EDTA-Na 2 ·2 H 2 O, pH 7.4) and collected by centrifugation at 1,000×g for 10 min.
The cell pellet was suspended in ice-cold homogenization buffer (5 mM Tris/HCl, 5 mM EDTA-Na 2 ·2 H 2 O, 5 mM EGTA, 0.1 mM PMSF, pH 7.4) for 20 min and then centrifuged at 40,000×g for 10 min at 4°C. The membrane pellet was resuspended in 50 mM Tris/HCl buffer (pH 7.4) and centrifuged at 40,000×g for 10 min at 4°C. The final pellets were resuspended in reaction buffer (50 mM Tris/HCl, 2 mM MgCl 2 , pH 7.4). The protein concentration of the membranes was measured by the Bradford method and aliquots were stored at −80°C.
Radioligand binding assay
Radioligand binding assay was performed using a slightly modified protocol by Klotz et al. [12] . Thawed membranes containing 30 μg CHO-hA 1 ligand binding. The receptor binding data were analyzed using a non-linear regression model (GraphPad Software, San Diego, CA, USA). IC 50 values of PQ-69 or DPCPX were determined using the method described by Cheng and Prusoff [13] . K i values were calculated using the equation
is the concentration of radioligand and K d is dissociation constant; Cheng & Prusoff [13] ). All data are presented as mean values of two or three separate experiments. -10 −5 M). Each compound described above, when added to cells, required 30-min incubation at room temperature in the dark. Finally, cAMP levels were measured using homogeneous time- Preliminary pharmacokinetic evaluation PQ-69 and DPCPX (2 mg/kg) were intravenously administered in rats. The dosing solutions of PQ-69 and DPCPX were prepared in 65 % PEG400 and 35 % saline. Serial blood samples were collected at various times and centrifuged to obtain plasma. For sample analysis, 50 μL of plasma was added to 10 of acetonitrile and 150 μL of internal standard solution. The mixture was centrifuged at 18,800×g, 4°C for 10 min. The supernatant was then analyzed using high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters were calculated using a noncompartmental model in WinNonlin Professional (Version 5.2.1, Pharsight Corp; Mountain View, CA, USA). In vitro metabolic stability of PQ-69 and DPCPX was investigated using rat and human liver microsomes in procedures similar to those previously described [15] . The incubations (5 μM parent drug, 0.5 mg/ml microsomal protein, 0.1 M phosphate buffer) were started by the addition of 1 mM NADPH solution after a 5-min preincubation at 37°C and were terminated after 60 min. The amount of parent drug was analyzed by LC-MS/MS and the percent of remaining parent drug was calculated and compared. In vitro permeabilities of PQ-69 and DPCPX were carried out using a Caco-2 cell line, according to previously described methods [16] . In brief, drug solution (5 μM) was placed in the donor chamber and samples were taken from the receptor chamber at 90 min. Samples were analyzed by LC-MS/MS, then the apparent permeability coefficient (P app ) was calculated using the equation:
Diuretic effects in normal rats
Male Sprague-Dawley (SD) rats, weighing 200-300 g, were used in the present study. The animals were kept at 25°C in a 12-h light-dark cycle. They had free access to food and water. Animal care and procedures were strictly in accordance with The Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Diuretic effects of compounds in normal rats were determined with a slight modification of the previous method [17] . In brief, rats were fasted for 24 h, and the drug suspension or the vehicle (EtOH/PEG400/H 2 O = 1:5:4) was intravenously administered to the rat at a volume of 4 ml/kg. After the administration, rats were housed individually in metabolic cages without food and water. Urine was collected every 4 h, and the urinary volume and concentration of sodium in the urine were measured.
Data and statistical analysis
Data were expressed as mean±S.E.M. Statistical analysis of experiments was performed using Prism software (Graph Pad software) including unpaired Student's t test for two-group comparison and one-way ANOVA with Tukey's multiple comparison test for multiple group comparisons. P values less than 0.05 were regarded as statistically significant.
Results
Chemistry
Aided by the 3D structural insights into the interaction between non-xanthinic ligands with A 1 AR [12] , a series of novel 4-alkylamino substitution 2-arylpyrazolo[4,3-c]quinolin-3-one derivatives were designed and synthesized. PQ-69 and its analogues (Supplementary Table 1) were prepared according to the procedure depicted in Scheme 1. Various commercially available isatoic anhydride (I) as starting material were reacted with sodium hydride followed by diethyl malonate in DMF at 120°C to afford 2,4-dihydroxy-3-quinolinecarboxylic acid ethyl ester derivatives (II) in moderate yield. Compounds (II) upon treatment with phosphorus oxychloride and phosphorus pentachloride at 110°C gave the unstable 2,4-dichloro-3-quinolinecarboxylic acid ethyl ester derivatives (III) in good yield. Reaction of 2,4-dichloro compounds (III) with appropriate amines in refluxing methanol afforded 2-alkylamino substituted 4-chloride-3-quinolinecarboxylic acid ethyl ester (IV) 4-chloro of which was replaced with appropriately substituted phenylhydrazine and simultaneously cyclized to target compounds(V) in refluxing ethanol, which were purified by column chromatography on silica gel.
Pharmacology
Identification and characterization of the PQ-69 molecule
The preliminary results of the receptor radioligand binding assay revealed a hit from this class of compounds with good affinity for the A 1 AR. Investigated compounds for affinity at hA 1 , hA 2A and hA 3 ARs expressed on CHO or HEK293 cells were listed in Table 1 , demonstrating that PQ-69 had the highest binding affinity for the A 1 AR over other adenosine receptors. In comparison with DPCPX, the K i value of PQ-69 on A 1 AR was 0.96 nM, which was lower than that of DPCPX (1.9 nM in our current study). By contrast, the K i values of PQ-69 and DPCPX for A 2A AR were 208 and 100 nM, respectively. The selectivity of PQ-69 on A 1 AR over A 2A AR was 217-fold, which is much higher than that of DPCPX (52-fold). These results suggested that PQ-69 has higher affinity and selectivity to A 1 AR than DPCPX. Interestingly, we found a 13-fold increase in affinity of PQ-69 for rat brain membrane 2 nM) , suggesting that PQ-69 was more potent than DPCPX in antagonizing the R-PIA-induced G protein activation.
Antagonistic effect and inverse agonistic activity of PQ-69 compared with DPCPX on cAMP response To further demonstrate the characteristic of antagonists with inverse agonist activity, the effects of the compounds on cAMP contents of intact CHO-hA 1 AR cells were observed. As shown in Fig. 2a (Fig. 2b) . It was also found that PQ-69 and DPCPX had very weak effects on the inhibitory action of NECA (10 μM) on cAMP concentration in HEK-293-hA 2A AR cells with IC 50 values of 3.5 and 1.56 μM, respectively (data not shown). These results suggested that PQ-69 and DPCPX were both selective A 1 AR antagonists with inverse activities, but PQ-69 was more potent than DPCPX.
Antagonist action of PQ-69 compared with DPCPX on contractive responses of isolated guinea pig trachea induced by CCPA In isolated guinea pig trachea, CCPA-induced contractile responses in a concentration-dependent manner (0.01-10 μM). pA2 values and Schild plots have been shown in Table 2 . All data are mean±S.E.M from three independent experiments, performed in duplicate. Curves were fitted using dose-response analysis Schild plots of DPCPX and PQ-69 were not significantly different from unity. Affinity estimates (pA2 values) of PQ-69 were slightly different from that of DPCPX. PQ-69 was slightly more potent with a pA2 value of 8.99 than that of DPCPX (8.11 ). This finding indicated that PQ-69 was a potent competitive antagonist on CCPA-induced tracheal contraction.
Pharmacokinetic studies
The pharmacokinetic profiles of PQ-69 and DPCPX were first determined in SD rats after intravenous administration. As shown in Table 3 , PQ-69 displayed longer terminal elimination half-life (t 1/2 ) with 7.92 h compared with 2.36 h for DPCPX. However, the total plasma clearance of PQ-69 was similar to DPCPX. Furthermore, a larger volume of distribution was found for PQ-69 with 25.5 L/kg compared with DPCPX (7.11 L/kg). By contrast, PQ-69 displayed better metabolic stability and broader tissue distribution than DPCPX. Therefore, the large tissue distribution balanced the slow metabolism. For subsequent experiments, the difference in liver metabolism was also evaluated using an in vitro microsomal stability assay. After 60 min incubation in rat liver microsomes, the percentage of remaining parent drugs was significantly different between PQ-69 (73.5±2.6 %) and DPCPX (30.1±3.4 %). Therefore, we have shown that PQ-69 displayed better metabolic stability in rat liver microsomes compared with DPCPX. The absorptive permeability (P app ) of PQ-69 was measured using a Caco-2 transport assay. The results indicated that both PQ-69 and DPCPX had moderate permeability across epithelial cells.
Diuretic effects in normal rats
Finally, we observed the diuretic effect and natriuretic effect of PQ-69 in normal rats compared with DPCPX, FURO and HCTZ. In Fig. 3a , PQ-69 (0.03, 0.3, 3 mg/kg) significantly increased urine flow by 82-162 % compared with that in the vehicle group. DPCPX (1 mg/kg), HCTZ (1 mg/kg) and Fig. 3b , the concentration of sodium increased significantly in all the drug-treated groups compared with the vehicle group. Sodium concentration was increased by 120-306 % in rats treated with PQ-69 (0.03, 0.3, 3 mg/kg), by 162 % in rats treated with DPCPX (1 mg/kg), by 214 % in rats treated with HCTZ (1 mg/kg) and by 214 % in rats treated with FURO (6 mg/kg). FURO (6 mg/kg) caused significantly greater renal excretion of sodium than PQ-69, DPCPX or HCTZ at higher doses. The natriuretic activity of PQ-69 (0.3 mg/kg) was similar to HCTZ (1 mg/kg) with urinary Na + of 1.6 and 1.78 mmol/kg/4 h, respectively; meanwhile, PQ-69 (3 mg/kg) was equivalent to DPCPX (1 mg/kg) with urinary Na + of 2.33 and 2.19 mmol/kg/4 h, respectively.
Discussion
To identify potent and A 1 AR-selective antagonists, we have designed and synthesized a series of novel 4-substituent-2-arylpyrazolo[4,3-c]quinolin-3-one derivatives. On the basis of knowledge obtained from the lead optimization project, a putative structure-activity relationship model was proposed.
(i) A common feature of these compounds with A 1 AR affinities is a quinofused five-member nitrogen-containing heterocyclic nucleus as a template, with aromatic or π electron-rich planar molecular architecture.
(ii) The substituents, i.e. 2-aryl, 3-carbonyl and 4-alkylamino, are indispensable structural factors for making the compounds biologically active. (iii) The specific substituents in the specific positions of the three aromatic rings have a synergistic effect on the contributions to the biological activity of the compounds. That is, the affinities to A 1 AR of compounds are the result of the three sets of substituents acting together. (iv) At the same time, the substituents appended on the quinoline ring, 2-aryl as well as 4-alkylamino, largely contribute to the solubility of compounds. PQ-69 was identified as a result of radioligand binding assay, ex vivo and in vivo biological evaluations together with a thorough lead optimization programme. PQ-69 was identified as an ideal candidate for further research showing nearly a fourfold longer t 1/2 than that of DPCPX in rats and also better metabolic stability in the human hepatic microsomal enzyme incubation experiment in vitro ( Table 3 ), suggesting that PQ-69 has even better pharmacokinetic properties than DPCPX.
In the present study, the pharmacological profiles of PQ-69 were evaluated through various in vivo and in vitro experiments. Simultaneously, we performed all in vitro pharmacological studies on human A 1 AR in view of apparent species differences between humans and rats. Consistent with previous studies, DPCPX displayed moderate affinity and selectivity for human A 1 AR in a recombinant expressed human adenosine receptor mammalian cell system. The results from radioligand binding experiments revealed that PQ-69 displayed a more than twofold increase in A 1 AR affinity and fourfold increase in A 1 AR selectivity compared with those of DPCPX. Furthermore, even at a concentration of 0.1 μM, PQ-69 had no effect on the binding for α 1A -and α 1B -adrenoceptors, ß-adrenoceptors, dopamine D 1 , D 2 and D 3 receptors or muscarinic M 4 and M 5 receptors overexpressed in CHO or HEK-293 cell line systems (data not shown).
In addition to activation of A 1 AR-coupled G i/o protein, cAMP is the key molecule in reflecting A 1 AR activation or antagonism. In this study, PQ-69 appeared to be a more potent antagonist than DPCPX in mammalian cells in functional [
35 S]-GTPγS binding and cAMP assays. Moreover, we also found that PQ-69 exhibited higher selective antagonism at A 1 AR than DPCPX with an IC 50 at A 2A AR of 3.5 and 0.14 μM, respectively (data not shown).
Given that PQ-69 appeared to be a more potent and selective A 1 AR antagonist than DPCPX in vitro, we tried to relate antagonist studies made in recombinant systems to more physiologically relevant settings, such as isolated tissues or in vivo studies. We further assessed the antagonizing activity of PQ-69 and DPCPX on CCPA-induced isolated guinea pig tracheal strips.
Both PQ-69 and DPCPX significantly antagonized the inhibition by CCPA of the contraction of tracheal strips. The higher pA2 value of PQ-69 in isolated guinea pig tracheal strips indicated higher antagonism compared with DPCPX. Moreover, PQ-69 was found to relax tonic contractions of guinea pig tracheal strips in a concentrationdependent manner (10 −10 -10 −6 M; data not shown) suggesting that the antagonism by PQ-69 was mediated by blockade of endogenous A 1 AR. Therefore, the above results indicated that PQ-69 might be a potent and highly selective A 1 AR antagonist. Interestingly, in this study, DPCPX was identified as an inverse agonist in a recombinant mammalian cell system, consistent with previous studies [9, 10] . DPCPX behaved as an inverse agonist by directly decreasing basal G protein activation and increasing intracellular cAMP in vitro tests. Moreover, compared with DPCPX, 16-fold more potent A 1 AR inverse agonist activity of PQ-69 was detected in a [ 35 S]-GTPγS binding assay, but only 8-fold inverse agonist activity was seen when measuring increasing cAMP production. A possible explanation for our observation is that significant variation in cell culture is attributed to differences in expression patterns of second messenger systems. Therefore, PQ-69 is a selective antagonist and inverse agonist at the A 1 AR.
Notably, native systems are of particular importance for analysing the in vivo relevance of constitutive activity because these systems have physiological expression levels of target receptors. The exact inverse agonist property of PQ-69 needs further in vivo studies.
In this study, the bioactivity of PQ-69 became more potent as the experimental system advanced from the in vitro molecular level to the cellular level and then to in vivo experiments. DPCPX potently promoted diuresis and natriuresis at the dose of 0.1 mg/kg in anaesthetized rats, which results from the blockade of endogenous adenosine modification on renal excretory function via stimulation of the A 1 AR subtype. In our study, PQ-69 increased urine flow and natriuresis at the dose of 0.03 mg/kg. PQ-69 and DPCPX both displayed similar diuretic efficacy to thiazide diuretics.
Levels of extracellular adenosine are usually enough to tonically activate inhibitory A 1 ARs. Therefore, adenosine antagonists with improved therapeutic potential application mainly are dependent on the level of endogenous purinergic tone instead of the absolute distribution of receptors. Whether the more potent inverse agonist characteristics of PQ-69 were related to the diuretic effects in the kidney remains to be determined. Thus, to elucidate whether PQ-69 is either a true antagonist or inverse agonist requires continued detailed exploration in vivo.
In conclusion, PQ-69 is one of the most potent and selective non-xanthine A 1 AR antagonists yet described. The selectivity profile of PQ-69 for A 1 AR vs A 2A AR was 52-fold compared with 217-fold on human A 1 R, and was superior to that of DPCPX. Moreover, PQ-69 displayed more potent inverse agonistic activity for A 1 AR than DPCPX. We have demonstrated that PQ-69 has similar diuretic pharmacological properties to that of thiazide diuretics and DPCPX under normal conditions. Thus, PQ-69 represents a novel, potent and selective non-xanthine A 1 AR antagonist with pronounced inverse agonist activity and in vivo bioactivity. This novel compound will be a useful tool to characterize physiological functions and complicated pathological conditions in relation to responses mediated by A 1 ARs.
